Citation Impact
Citing Papers
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
Formulation and Delivery Technologies for mRNA Vaccines
2020
Lipid nanoparticles for mRNA delivery
2021 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
2023 StandoutNobel
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Checkpoint inhibitors in breast cancer – Current status
2017
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
The clinical progress of mRNA vaccines and immunotherapies
2022
Recent developments in immunotherapy of cancers caused by human papillomaviruses
2020
Works of Mary Macri being referenced
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
2018
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
2021
Abstract B209: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)
2019
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.
2017